Document is current

Any future updates will be listed below

A rebuttal letter to the letter ID number CLRH-D-21–00,836 entitled “On the efficacy and safety of rituximab therapy in patients with systemic sclerosis disease: missing points, bottlenecks, over-exaggeration and discrepancies”

Crossref DOI link: https://doi.org/10.1007/s10067-021-05832-2

Published Online: 2021-09-13

Published Print: 2021-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark